Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report Authors: Chan-Ho Cho, Won Jae Kim Published: 2026 ABSTRACT AbstractSemaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for obesity management; however, concerns have recently emerged regarding potential ocular adverse events, including nonarteritic anterior ischemic optic neuropathy (NAION). Herein, we report a case of NAION that developed after marked, rapid weight loss during semaglutide therapy in a young man with multiple vascular risk factors. A 42-year-old man presented with acute visual disturbance in the right eye after losing approximately 40 kg over 2 months while receiving semaglutide (Wegovy) for obesity treatment. The patient’s medical history included diabetes mellitus, hypertension, dyslipidemia, and a history of smoking. Ophthalmic examination revealed right optic disc edema and a corresponding inferior visual field defect. Magnetic resonance imaging and laboratory investigations revealed no other definite causes of optic neuropathy. He was diagnosed with NAION, which was temporally associated with semaglutide therapy and rapid weight reduction. Semaglutide was discontinued, and high-dose intravenous methylprednisolone was administered. At 6 months, the optic disc edema had resolved, leaving mild disc pallor, though the visual field defect persisted. Although causality cannot be established from a single case, this report highlights the need for clinical vigilance regarding optic neuropathy in patients receiving semaglutide, particularly in the setting of rapid weight loss.Keywords: Semaglutide, Optic Neuropathy, Anti-Obesity Agents, Optic Atrophy, Case Reports Introduction Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for the management of both diabetes mellitus and obesity [1,2]. With its expanding use, various systemic adverse events have been reported, and potential ocular complications, including nonarteritic anterior ischemic optic neuropathy (NAION), have received increasing attention [3-6]. Although recent epidemiological studies have raised concerns regarding this potential association, clinical case reports remain scarce, particularly in Asian populations. Herein, we report, to the best of our knowledge, the first case of NAION in South Korea that developed after marked and rapid weight loss during semaglutide therapy in a relatively young man with multiple vascular risk factors. Case Report A 42-year-old man presented to Yeungnam University Hospital with visual disturbances in the right eye. The patient reported blurred vision involving the inferior visual field of the right eye; however, the exact onset was unclear. He denied ocular pain, headache, or other neurological symptoms. His medical history included type 2 diabetes mellitus and hypertension, both diagnosed 10 years earlier and treated with oral medications (Janumet XR 100/1,000 mg, Actos 30 mg, Dilatrend 25 mg, and Exforge 10/160 mg). Comorbidities also included dyslipidemia, managed with Vivacor 10 mg, and he was receiving low-dose aspirin (Astrix 100 mg) for primary cardiovascular prevention. He had a 15-year history of smoking approximately one pack of cigarettes per day. Upon presentation, his height was 168.3 cm and body weight was 93.4 kg. He reported losing approximately 40 kg over the preceding 2 months while receiving semaglutide (Wegovy, Novo Nordisk) injections for obesity treatment. Semaglutide was initiated at 0.25 mg and gradually increased to 1.7 mg according to the usual step-up regimen. He had maintained the 1.7 mg dose for approximately 2 months prior to onset of visual symptoms. During the weight-loss period, he exercised for approximately 2 hours per day and denied experiencing adverse gastrointestinal events or other semaglutide-related tolerability issues. On ophthalmic examination, best-corrected visual acuity was 20/20 in both eyes. Intraocular pressure was 18 mm Hg in the right eye and 17 mm Hg in the left eye. Pupillary light and near reflexes were intact, and color vision testing revealed no abnormalities. Fundus examination revealed optic disc edema in the right eye, with blurred disc margins and peripapillary swelling (Figure 1A, B). Standard automated perimetry (Humphrey Field Analyzer, Carl Zeiss Meditec) revealed a localized inferior visual field defect in the right eye, consistent with the patient’s subjective complaints (Figure 1C, D). Initial ophthalmic findings in a 42-year-old man who developed nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy. (A) Color fundus photograph of the right eye (OD) showing a swollen hyperemic optic disc with blurred margins and vascular engorgement (arrow). (B) Color fundus photograph of the left eye (OS) showing a normal optic disc appearance. (C) Humphrey 30-2 visual field of the right eye showing an inferior altitudinal-like visual field defect with relative central sparing (arrowhead). (D) Humphrey 30-2 visual field of the left eye showing no significant visual field abnormality. Laboratory investigations, including tests for serum anti-aquaporin-4 and anti-myelin oligodendrocyte glycoprotein antibodies, were unremarkable. Magnetic resonance imaging of the brain and orbits demonstrated equivocal bulging of the right optic disc but no abnormal signal change or contrast enhancement in either optic nerve. Based on the unilateral optic disc edema, corresponding visual field defect, negative inflammatory and demyelinating workup, and presence of multiple vascular risk factors, we diagnosed NAION, which was considered to be temporally associated with semaglutide use and rapid weight loss. The patient was counseled about the generally guarded visual prognosis of NAION. In the absence of an established effective acute treatment and after discussion with the patient, high-dose intravenous methylprednisolone (1 g/d for 3 days) was administered empirically, and semaglutide was discontinued. At the 6-month follow-up, fundus examination showed resolution of the disc swelling with mild optic disc pallor, whereas the inferior visual field defect persisted (Figure 2A–C). Optical coherence tomography (Carl Zeiss Meditec) demonstrated thinning of the ganglion cell-inner plexiform layer, corresponding to the visual field defect (Figure 2D). Follow-up ophthalmic findings 6 months after the initial presentation in a 42-year-old man with nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy. (A) Color fundus photograph of the right eye (OD) showing resolution of optic disc swelling with residual mild disc pallor (arrow). (B) Color fundus photograph of the left eye (OS) showing a normal optic disc appearance. (C) Humphrey 30-2 visual field of the right eye showing a persistent inferior altitudinal-like visual field defect with relative central sparing. (D) Optical coherence tomography macular ganglion cell analysis demonstrating ganglion cell-inner plexiform layer thinning in the right eye corresponding to the visual field defect, with no significant abnormality in the left eye (arrowhead). The patient provided written informed consent for the publication of research details and clinical images. Discussion This case illustrates that occurrence of NAION in a relatively young man with long-standing vascular risk factors following rapid weight loss associated with semaglutide therapy. Although a definitive causal relationship cannot be established from a single case, the temporal association between NAION onset, semaglutide use, and rapid weight loss, together with emerging epidemiological evidence, suggests that semaglutide therapy and/or rapid weight loss may have contributed or precipitated the development of NAION in this patient. NAION is one of the most common causes of acute optic neuropathy in adults and typically presents with sudden, painless monocular vision loss accompanied by optic disc edema [7]. Because no proven treatment can reverse established visual loss, recognition of potential risk factors is clinically important. NAION typically occurs in individuals older than 50 years and is strongly associated with systemic risk factors such as diabetes, hypertension, dyslipidemia, smoking, as well as a small, crowded “disc-at-risk” optic nerve head anatomy [7]. Our patient had multiple conventional risk factors; however, at 42 years of age, he was younger than the typical NAION population. In addition, although pre-event ophthalmic records were unavailable and optic disc anatomy could not be assessed during the acute edematous phase, follow-up fundus photographs after the resolution of the disc swelling did not suggest a markedly small or crowded disc. These findings suggest that the case was not entirely typical of conventional NAION and that an additional precipitating factor may have further reduced the perfusion reserve of the optic nerve head. The possible association between semaglutide and NAION was reported by Hathaway et al. [4] in 2024, who observed an increased risk of NAION among semaglutide users in a neuroophthalmology-based cohort. Subsequent studies, however, have yielded inconsistent results. Several investigations, including those by Cai et al. [3], Hsu et al. [5], and Simonsen et al. [6], supported a positive association. However, other studies, such as those by Abbass et al. [8] and Chou et al. [9], did not find a significant increase in risk. These discrepancies may be explained by important methodological differences across studies, including case ascertainment, study population, comparator selection, and duration of follow-up [10]. In particular, the study by Hathaway et al. [4] had the advantage of clinically adjudicated NAION diagnoses made by neuro-ophthalmologists, which likely improved diagnostic specificity, whereas several larger database studies relied primarily on diagnostic coding and were therefore more susceptible to outcome misclassification. Conversely, broader database studies may better reflect the general population and offer greater statistical power, but at the cost of less precise phenotyping [8,9]. Several mechanisms have been proposed to explain the potential link between semaglutide and NAION [3-5,10]. However, the relative contributions of the possible direct drug-related effects and indirect effects associated with rapid weight loss remain unclear. Direct effects of semaglutide on optic nerve head perfusion and vascular regulation cannot be excluded. In addition, rapid weight loss associated with semaglutide, particularly when accompanied by reduced oral intake or gastrointestinal adverse effects, may lead to relative hypovolemia, dehydration, and systemic hypotension, thereby compromising optic nerve head perfusion [8]. Rapid metabolic and hemodynamic shifts during substantial weight loss may also worsen preexisting microvascular dysfunction and impair vascular autoregulation in susceptible patients. In the present case, the patient had multiple conventional vascular risk factors, including diabetes mellitus, hypertension, dyslipidemia, and a history of smoking, which may have increased his underlying susceptibility to NAION. Because NAION has no established treatment and visual prognosis is often poor, prevention may be more important than recognition after the development of visual symptoms during semaglutide therapy. Given the proven efficacy of semaglutide for weight loss and its beneficial effects on obesity-related comorbidities, its use will likely continue to expand [1,2,4]. Therefore, an important future priority is not only to further clarify the potential association between semaglutide and NAION but also to identify safer treatment strategies for patients at risk. In particular, it is important to determine whether the speed and magnitude of weight loss during therapy contribute to NAION development in susceptible individuals. Such evidence may ultimately be more clinically valuable than establishing the presence or absence of an association alone because it could help inform practical guidance on risk stratification, monitoring, patient selection, and safer weight-reduction trajectories during treatment. This study has some limitations. Baseline ophthalmologic data before semaglutide initiation were unavailable; therefore, the preexisting optic nerve head anatomy could not be definitively assessed. In addition, the temporal association among semaglutide therapy, rapid weight loss, and NAION should be interpreted with caution and not be regarded as evidence of a causal relationship. Further multicenter ophthalmologic studies with detailed clinical characterization are needed to better characterize similar cases and clarify the potential mechanisms underlying NAION during semaglutide therapy and rapid weight reduction. In conclusion, we describe a case of NAION that developed after marked and rapid weight loss during semaglutide therapy in a 42-year-old man with multiple vascular risk factors. This case highlights the need for clinical awareness of optic neuropathy in patients receiving semaglutide, particularly when weight loss is rapid and substantial. Footnotes Conflict of interest No potential conflict of interest relevant to this article was reported. Funding None. Data availability Not applicable. Author contribution Conceptualization: WJK. Investigation: all authors. Supervision: WJK. Writing–original draft: WJK. Writing–review & editing: all authors. Final approval of the manuscript: all authors. References